Multimodal Modulation of the IL-17 Axis: Integrating Small-Molecule Inhibition, PEGylation, and Targeted Nanoparticle Immunotherapy
Abstract
Recent patent disclosures reveal convergent strategies to modulate IL-17-driven pathology through complementary chemical and delivery modalities. Acidic small-molecule inhibitors, PEGylated derivatives, and antibody-functionalized lipid nanoparticles collectively address potency, exposure, and immune context. Together, these approaches outline an integrated framework for treating inflammatory diseases and immunosuppressive tumor microenvironments.
Fields of Study & Subjects
Psoriasis: Treatment and Pathogenesis
Cytokine Signaling Pathways and Interactions
Cancer Immunotherapy and Biomarkers
Publication details
- Journal / source
- ACS Medicinal Chemistry Letters
- Volume
- 17
- Issue
- 2
- Pages
- 309–311
- Publication date
- 12 January 2026
- Language
- EN